Melanoma cases rise in women under 50
Melanoma cases are rising in younger people, particularly in women under 50, a National Cancer Institute study has found.
Why it matters: Skin cancer is the most common cancer in the U.S., and melanoma is the deadliest type.
Between the lines: Many cases are preventable.
Exposure to UV light from the sun or indoor tanning beds causes most melanoma cases, per NCI data.
Young women are still most likely to indoor-tan, even though their tanning rates declined after 2010, per the most recent data available.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Historic vote brings assisted dying closer to becoming law in England and Wales
Assisted dying is a step closer to being made legal in England and Wales after the proposed legislation cleared the House of Commons in a historic vote. A majority of MPs backed a Bill that would allow terminally ill adults with a life expectancy of less than six months to end their lives. Despite warnings from opponents around the safety of a Bill they argued has been rushed through, the proposed legislation took another step in the parliamentary process. MPs voted 314 to 291, majority 23, to approve Kim Leadbeater's Terminally Ill Adults (End of Life) Bill at third reading. This means the Bill has completed its first stages in the Commons and will move to the House of Lords for further debate and scrutiny. Both Houses must agree the final text of the Bill before it can be signed into law. Due to the four-year implementation period, it could be 2029 – potentially coinciding with the end of this Government's Parliament – before assisted dying is offered. Encouraging or assisting suicide is currently against the law in England and Wales, with a maximum jail sentence of 14 years. Supporters of assisted dying have described the current law as not being fit for purpose, with desperate terminally ill people feeling the need to end their lives in secret or go abroad to Dignitas alone, for fear loved ones will be prosecuted for helping them. Friday was the first time the Bill was debated and voted on in its entirety since last year's historic yes vote, when MPs supported the principle of assisted dying for England and Wales by a majority of 55 at second reading. Labour MP Ms Leadbeater has argued her Bill will 'correct the profound injustices of the status quo and to offer a compassionate and safe choice to terminally ill people who want to make it'. During an hours-long date on Friday, MPs on both sides of the issue recalled personal stories of loved ones who had died. Conservative former minister Sir James Cleverly, who led the opposition to the Bill in the Commons, spoke of a close friend who died 'painfully' from cancer. He said he comes at the divisive issue 'not from a position of faith nor from a position of ignorance', and was driven in his opposition by 'concerns about the practicalities' of the Bill. MPs had a free vote on the Bill, meaning they decided according to their conscience rather than along party lines. The proposed legislation would allow terminally ill adults in England and Wales, with fewer than six months to live, to apply for an assisted death, subject to approval by two doctors and a panel featuring a social worker, senior legal figure and psychiatrist. Public support for a change in the law remains high, according to a YouGov poll published on the eve of the vote. The survey of 2,003 adults in Great Britain, suggested 73% of those asked last month were supportive of the Bill, while the proportion of people who feel assisted dying should be legal in principle stood at 75%.
CNN
40 minutes ago
- CNN
Britain's lawmakers vote to legalize assisted dying, a landmark move after a fraught national debate
Lawmakers in Britain have narrowly approved a bill to legalize assisted dying for terminally ill people, capping a fraught debate in Parliament and across the country that cut across political, religious and legal divides. MPs passed the bill by 314 votes to 291, in their final say on the question. The bill – which has split lawmakers and sparked impassioned conversations with their constituents the breadth of Britain – will now move to the House of Lords for its final rounds of scrutiny. Friday's vote puts Britain firmly on track to join a small club of nations that have legalized the process, and one of the largest by population to allow it. It allows people with a terminal condition and less than six months to live to take a substance to end their lives, as long as they are capable of making the decision themselves. Two doctors and a panel would need to sign off on the choice. Canada, New Zealand, Spain and most of Australia allow assisted dying in some form, as do several US states, including Oregon, Washington and California. Friday's vote in Parliament coincided with a charged public debate about whether the state should be dictating the choices available to Britons in the final moments of their lives. Proponents included Esther Rantzen, a BBC TV presenter with advanced lung cancer, who argued that the choice would save millions from unnecessary suffering. 'If we don't vote to change the law today, what does that mean?,' asked Kim Leadbeater, the MP who introduced the bill last year. 'It means we will have many more years of heartbreaking stories from terminally ill people and their families, of pain and trauma, suicide attempts, PTSD, lonely trips to (clinics in) Switzerland, police investigations.' The option, she said, is 'not a choice between living and dying: it is a choice for terminally ill people about how they die.' But opponents have criticized the bill on religious and ethical grounds, and raised issues with a legislative process they accuse of being opaque. Former British Prime Minister Gordon Brown argued that fixing Britain's strained end-of-live care system should be prioritized, writing in a rare intervention in The Guardian that the bill 'would privilege the legal right to assisted dying without guaranteeing anything approaching an equivalent right to high-quality palliative care for those close to death.' Seriously ill people 'need the health and social care system fixing first,' Labour MP Vicky Foxcroft said in Parliament Friday. 'They want us as parliamentarians to assist them to live, not to die.' Friday's debate was concluded with a free vote, meaning that MPs were allowed to decide for or against the bill according to their conscience, and free from any party-line whipping. The proposed bill is broadly in line with the Oregon model, and does not go as far as Switzerland, the Netherlands and Canada, which allow assisted death in cases of suffering, not just for terminally ill people. It differs from euthanasia, the process in which another person deliberately ends someone's life to relieve suffering. It is currently a crime to help somebody die in England and Wales, punishable by up to 14 years in prison. Performing euthanasia on a person, meanwhile, is considered murder or manslaughter.
Yahoo
44 minutes ago
- Yahoo
United States Diabetes Devices and Therapeutics Market Investment Opportunities Report 2025
The U.S. diabetes market is projected to grow at a CAGR of 7.2% from 2025-2029, reaching $39.33 billion. Key trends include real-time monitoring adoption, digital health integration, advanced delivery systems, and supportive regulatory frameworks. The report provides a data-centric analysis of market dynamics and opportunities. U.S. Diabetes Devices and Therapeutics Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "United States Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in United States is expected to grow by 8.4% on annual basis to reach US$27.62 billion in diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 9.1%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.2% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 25.47 billion to approximately USD 39.33 billion. The U.S. diabetes devices and therapeutics market is undergoing significant shifts with real-time monitoring, digital integration, advanced delivery systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures while emphasizing data integration and precise patient management. The U.S. diabetes devices and therapeutics market is characterized by a mix of established players and new entrants. Strategic partnerships, acquisitions, and the integration of digital health solutions are reshaping competitive dynamics. In the coming years, market consolidation and targeted innovation are expected to further define the competitive environment, influencing product offerings and patient management Adoption of Real-Time Glucose Monitoring U.S. healthcare providers increasingly use continuous glucose monitoring (CGM) systems to track patient glucose levels in real-time. Large healthcare networks have adopted CGM systems to support outpatient diabetes management. Recent publications indicate improvements in insurance reimbursement policies and favorable regulatory reviews. Enhanced clinical data on the reliability of CGM systems reinforces their use in routine diabetes care. Adoption is expected to increase, driven by wider coverage and enhanced device integration with electronic health records. The trend will likely intensify as more clinical studies validate the benefits of real-time monitoring in reducing long-term complications. Integrate Digital Health Solutions into Diabetes Management U.S. providers are integrating device data with telehealth platforms and remote patient monitoring systems for diabetes management. Examples include healthcare systems deploying centralized digital dashboards to monitor patient metrics remotely. Recent industry reports highlight a shift in healthcare delivery models that suggests a push toward digital transformation in chronic disease management. Insurance models increasingly support telehealth consultations and remote monitoring, aligning with broader medtech trends. The integration of digital platforms is expected to grow, promoting data-driven decision-making and enhancing care coordination. This trend will likely intensify, leading to a more efficient tracking of treatment adherence and patient outcomes. Advance Therapeutic Delivery Systems The market is witnessing the emergence of devices that support precise therapeutic delivery, such as smart insulin pens. U.S. manufacturers are introducing systems for accurate dosing and treatment adherence monitoring. Technological advancements in device miniaturization and data analytics are facilitating the development of these delivery systems. Recent healthcare publications note a rising focus on improving patient safety and treatment precision in diabetes care. Market penetration of smart delivery systems is expected to grow, influenced by evolving clinical practice guidelines and supportive reimbursement frameworks. This trend will intensify as precision therapy becomes a central focus in diabetes management. Regulatory and Reimbursement Frameworks Recent changes in FDA and CMS policies support integrating digital tools in diabetes care. Updated guidelines and expanded reimbursement criteria for digital health applications evidence these regulatory adjustments. Broader healthcare policy initiatives for cost containment and improved patient outcomes drive these regulatory changes. Publications from the past year highlight a response to the increased demand for remote monitoring and digital therapeutics. Regulatory support is expected to maintain momentum, enabling continued investment in digital health and advanced therapeutics. The framework will further intensify market adoption of compliant and data-integrated devices. Current Market ConditionsThe market comprises established manufacturers and emerging firms. A diverse portfolio of devices and therapeutics is present, ranging from established CGM systems to new smart delivery devices. Assess Key Competitors and Emerging Entrants Major companies, such as large medical device manufacturers and specialized diabetes care firms, hold significant market share. Established firms maintain comprehensive product portfolios covering both devices and therapeutics. New market entrants focus on integrating digital health solutions with diabetes management systems. These entrants bring targeted innovations, complementing the existing product mix in the U.S. market. Examine Strategic Partnerships and Corporate Activities Recent publications document acquisitions of smaller digital health companies by established device manufacturers. Strategic partnerships have been initiated between healthcare systems and technology firms to expand remote monitoring capabilities. The market shows signs of consolidation driven by competitive pressures and regulatory incentives. Collaborative efforts are aimed at enhancing integrated care delivery and data analytics capabilities. Future Competitive Dynamics Continued consolidation and strategic alliances are expected as established players seek to enhance their technological offerings. New entrants with digital health expertise will likely drive niche innovations, altering competitive positioning. Over the next 2-4 years, the competitive landscape will likely evolve with intensified competition and targeted market consolidation. Companies will increasingly leverage partnerships to improve patient data integration and therapeutic outcomes. Key Attributes: Report Attribute Details No. of Pages 50 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $29.83 Billion Forecasted Market Value (USD) by 2029 $39.33 Billion Compound Annual Growth Rate 7.2% Regions Covered United States ScopeDiabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
